Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China

ws_admin

5 days ago

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow